Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with open angle glaucoma or ocular hypertension~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 ophthalmic solution (Group1) (Type: EXPERIMENTAL): Monotherapy
- DE-117 ophthalmic solution (Group2) (Type: EXPERIMENTAL): Monotherapy
- DE-117 ophthalmic solution + Timolol (Group3) (Type: OTHER): Concomitant Use

Based on this trial design, predict the completion outcome and termination type (if applicable).